ORGANIGRAM GLOBAL INC.
For the period ended Dec 31, 2025. Filed Dec 31, 2025.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Dec 31, 2025 · Filed Dec 31, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Key Highlights:
Key Highlights:
US$3 million investment accelerates Organigram’s innovation strategy, providing access to next-generation genetics and strengthening its leadership in seed-based cultivation.
Industry-leading seed pipeline, with 30 new, next-generation genetics delivered twice annually through 2030, supporting innovation for recreational and medical markets.
Five-year exclusive rights secured for Organigram’s chosen cannabis genetics in international markets, with flexibility to add new territories as global expansion continues.
TORONTO, ON, December 31, 2025 – Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada’s #1 cannabis company by market share 1, today announced the expansion of its innovation investment in Phylos Bioscience Inc. (“Phylos”), securing Organigram’s position as a leader in seed-based cannabis genetics. Through an amended loan and product agreement, Organigram gains priority access to Phylos’ autoflower genetics pipeline, including preferential economic terms and long-term rights in its international markets, establishing a foundation for product differentiation and growth in recreational and medical markets.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.